MedPath

SNIPR Biome ApS

SNIPR Biome ApS logo
🇩🇰Denmark
Ownership
Holding
Established
2017-01-01
Employees
11
Market Cap
-
Website
http://www.sniprbiome.com

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli PreTransplant

Phase 1
Recruiting
Conditions
E Coli Infections
Allogenic Transplant Patients
Interventions
Biological: SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli
Other: Placebo 10 mL
First Posted Date
2025-04-22
Last Posted Date
2025-05-21
Lead Sponsor
SNIPR Biome Aps.
Target Recruit Count
24
Registration Number
NCT06938867
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

John Hopkins University, Baltimore, Maryland, United States

and more 5 locations

A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

Phase 1
Completed
Conditions
E.Coli Infections
Bloodstream Infection
Interventions
Drug: Placebo
First Posted Date
2022-03-14
Last Posted Date
2023-05-17
Lead Sponsor
SNIPR Biome Aps.
Target Recruit Count
36
Registration Number
NCT05277350
Locations
🇺🇸

Medpace Clinical Pharmacology, Cincinnati, Ohio, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.